Literature DB >> 1992031

Early scintigraphic detection of experimental myocardial infarction in dogs with technetium-99m-glucaric acid.

C Orlandi1, P D Crane, D S Edwards, S H Platts, L Bernard, J Lazewatsky, M J Thoolen.   

Abstract

Recent data have generated some interest in technetium-99m-(99mTc) glucaric acid as an in vivo viability marker. We studied 99mTc-glucaric acid retention in canine models of myocardial ischemia (20-min occlusion of the LAD/40-min reperfusion), acute myocardial infarction (MI) (90-min LAD occlusion/3-hr reperfusion), and chronic MI (90-min occlusion and either 48-hr or 10-day reperfusion). Regional myocardial blood flow was measured by radiolabeled microspheres. No preferential uptake of glucaric acid was observed in ischemic but viable myocardium. The compound showed high affinity for necrotic myocardial tissue for several days following injury. The preferential uptake in infarcted tissue disappeared by 10 days following injury. This study shows that 99mTc-glucaric acid acts exclusively as a marker of necrosis in canine models of MI. Technetium-99m-glucaric acid may have clinical utility in early cardiac imaging of myocardial infarction and in differentiating recent from old injuries.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1992031

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  18 in total

1.  Avidity of technetium 99m glucarate for the necrotic myocardium: in vivo and in vitro assessment.

Authors:  B A Khaw; A Nakazawa; S M O'Donnell; K Y Pak; J Narula
Journal:  J Nucl Cardiol       Date:  1997 Jul-Aug       Impact factor: 5.952

2.  Differentiation of myocardial ischemia and necrosis by technetium 99m glucaric acid kinetics.

Authors:  R S Beanlands; T D Ruddy; L Bielawski; H Johansen
Journal:  J Nucl Cardiol       Date:  1997 Jul-Aug       Impact factor: 5.952

Review 3.  Role of nuclear cardiac imaging in myocardial infarction: postinfarction risk stratification.

Authors:  John J Mahmarian; Girish Dwivedi; Tultul Lahiri
Journal:  J Nucl Cardiol       Date:  2004 Mar-Apr       Impact factor: 5.952

4.  99mTc-glucarate kinetics differentiate normal, stunned, hibernating, and nonviable myocardium in a perfused rat heart model.

Authors:  David R Okada; Zhonglin Liu; Gerald Johnson; Delia Beju; Ban An Khaw; Robert D Okada
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-07-24       Impact factor: 9.236

5.  Technetium 99m glucarate: what will be its clinical role?

Authors:  M C Gerson; A J McGoron
Journal:  J Nucl Cardiol       Date:  1997 Jul-Aug       Impact factor: 5.952

6.  Myocardial kinetics of Tc-99m glucarate in low flow, hypoxia, and aglycemia.

Authors:  D R Okada; G Johnson; Z Liu; S D Hocherman; B A Khaw; K Y Pak; R D Okada
Journal:  J Nucl Cardiol       Date:  2003 Mar-Apr       Impact factor: 5.952

Review 7.  Rationale for the rational development of new cardiac imaging agents.

Authors:  D D Miller
Journal:  Ann Nucl Med       Date:  1993-11       Impact factor: 2.668

8.  Advances in radionuclide molecular imaging in myocardial biology.

Authors:  Alan R Morrison; Albert J Sinusas
Journal:  J Nucl Cardiol       Date:  2010 Jan-Feb       Impact factor: 5.952

Review 9.  Myocardial viability: what do we need?

Authors:  H Schoeder; M Friedrich; H Topp
Journal:  Eur J Nucl Med       Date:  1993-09

10.  99mTc glucarate high-resolution imaging of drug sensitive and drug resistant human breast cancer xenografts in SCID mice.

Authors:  Zhonglin Liu; Gail D Stevenson; Harrison H Barrett; George A Kastis; Michel Bettan; Lars R Furenlid; Donald W Wilson; James M Woolfenden; Koon Yan Pak
Journal:  Nucl Med Commun       Date:  2004-07       Impact factor: 1.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.